daunomycin

DRUG4 trials

Sponsors

SWOG Cancer Research Network, Dana-Farber Cancer Institute, Rutgers, The State University of New Jersey, St. Jude Children's Research Hospital

Conditions

Acute Lymphocytic LeukemiaAcute Myelogenous LeukemiaLeukemiaLymphoblastic Lymphoma

Phase 2

High Dose Ara-C (HDAC) and Interleukin-2 (IL-2) for Patients With Acute Myelogenous Leukemia (AML)

CompletedNCT00136448

Dana-Farber Cancer InstituteAcute Myelogenous Leukemia

Start: 1993-02-28End: 2007-09-30Target: 30Updated: 2011-03-10

CINJALL: Treatment for Children With Acute Lymphocytic Leukemia

CompletedNCT00176462

Rutgers, The State University of New JerseyAcute Lymphocytic Leukemia

Start: 2001-02-28End: 2008-09-30Updated: 2014-06-09

Phase 3

S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML

CompletedNCT00085709

SWOG Cancer Research NetworkLeukemia

Start: 2004-07-31End: 2014-08-31Updated: 2015-09-30

Unknown Phase

Treatment for Patients With Stage III or IV Non-Hodgkin Lymphoma

CompletedNCT00187122

St. Jude Children's Research HospitalLymphoblastic Lymphoma

Start: 1993-03-31End: 2004-06-30Updated: 2008-04-23

Related Papers

Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia

Haematologica2023-08-0327 citations

Characteristics and prognostic impact of<i>IDH</i>mutations in AML: a COG, SWOG, and ECOG analysis

Blood Advances2023-06-0250 citations

Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614)

Blood2018-11-29

Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies

Blood2018-04-0422 citations

Effect of Minimal Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia

Blood2015-12-031 citations

The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials

Blood2013-11-1514 citations

Prediction Of CR On Reinduction In Patients With Newly Diagnosed Acute Myeloid Leukemia Given Intensive Induction Regimens: A Report From SWOG and Cleveland Clinic

Blood2013-11-159 citations

Evaluation Of Which Patients Get a Second Course Of 3+7 On Cooperative Group Trials For Newly Diagnosed Acute Myeloid Leukemia: A Report From SWOG

Blood2013-11-156 citations